Skip to main content
Log in

MEN1 family with a novel frameshift mutation

  • Case Report
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Multiple endocrine neoplasm type 1 (MEN1) syndrome predisposes to the development of endocrine and non-endocrine tumors with an autosomal dominant pattern of inheritance. Different mutations have been found throughout the gene with a variable phenotype expression. The proband, a Caucasian man, was admitted to our department in 2001, at the age of 51 because of a 1-yr history of diarrhoea and hypertension. He reported a previous intestinal resection for bowel occlusion with a histological diagnosis of unspecified mesenchymal neoplasia. He had also undergone a left adrenalectomy for a large non-functioning adrenal adenoma. Subsequently, he had suffered from gastralgia and melena; a gastroduodenoscopy showed an erosive gastritis. His family history was negative for endocrine disorders. On physical examination, multiple abdominal cutaneous lipomas and facial angiofibromas were observed. Biochemical screening revealed a primary hyperparathyroidism and an increase in circulating levels of PRL, chromogranin-A, gastrin and glucagon. The whole body computed tomography (CT) scan, the 111In-octreotide scan and the pituitary magnetic resonance imaging (MRI) did not reveal any abnormality. The presence of small neuroendocrine tumors was suspected by a positron emission tomography uptake in the epigastric region. The endoscopic ultrasound revealed a pancreatic lesion sized 1.1 cm that is under evaluation. Direct DNA sequencing analysis of the proband MEN1 gene revealed the 579delG frameshift mutation in the exon 3. The genetic screening of the family revealed the same mutation in 3 out of 5 offspring. The biochemical screening revealed some features of the MEN1 syndrome in all three of them. In conclusion, a novel frameshift MEN1 mutation was found in kindred with an apparently negative family history. Our experience confirms that MEN1 syndrome is a complex and underestimated condition, unless specifically investigated by trained specialists.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001, 86: 5658–71.

    Article  CAS  PubMed  Google Scholar 

  2. Schussheim DH, Skarulis MC, Agarwal SK, et al. Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol Metab 2001, 12: 173–8.

    Article  CAS  PubMed  Google Scholar 

  3. Wermer P. Genetic aspects of adenomatosis of endocrine glands. Am J Med 1954, 16: 363–71.

    Article  CAS  PubMed  Google Scholar 

  4. Wermer P. Endocrine adenomatosis, peptic ulcer disease in a large kindered: inherited multiple tumors, mosaic pleiotropism in man. Am J Med 1963, 35: 205–8.

    Article  CAS  PubMed  Google Scholar 

  5. Larsson C, Skogseid B, Oberg K Nakamura Y, Nordenskjold M. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988, 332: 85–7.

    Article  CAS  PubMed  Google Scholar 

  6. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the genefor multiple endocrine neoplasia-type 1. Science 1997, 276: 404–7.

    Article  CAS  PubMed  Google Scholar 

  7. Agarwal SK, Lee Burns A, Sukhodolets KE, et al. Molecular pathology of the MEN1 gene. Ann NY Acad Sci 2004, 1014: 189–98.

    Article  CAS  PubMed  Google Scholar 

  8. Jin S, Mao H, Schnepp RW, et al. Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Res 2003, 63: 4204–10.

    CAS  PubMed  Google Scholar 

  9. Kim H, Lee JE, Cho EJ, et al. Menin, a tumor suppressor, represses JunD mediated transcriptional activity by association with an mSin3A-histone deacetylase complex. Cancer Res 2003, 63: 6135–9.

    CAS  PubMed  Google Scholar 

  10. Schnepp RW, Hou Z, Wang H, et al. Functional interaction between tumor suppressor menin and activator of S-phase kinase. Cancer Res 2004, 64: 6791–6.

    Article  CAS  PubMed  Google Scholar 

  11. Sowa H, Kaji H, Hendy GN, et al. Menin is required for bone morphogenetic protein 2- and transforming growth factor beta-regulated osteoblastic differentiation through interaction with Smads and Runx 2. J Biol Chem 2004, 279: 40267–75.

    Article  CAS  PubMed  Google Scholar 

  12. Agarwal SK, Kester MB, Debelenko LV, et al. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet 1997, 6: 1169–75.

    Article  CAS  PubMed  Google Scholar 

  13. Brandi ML. Multiple endocrine neoplasia type 1. Rev Endocr Metab Disord 2000, 1: 275–82.

    Article  CAS  PubMed  Google Scholar 

  14. Schussheim DH, Skarulis MC, Agarwal SK, et al. Multiple endocrine neoplasia type 1: new clinical and basicfindings. Trends Endocrinol Metab 2001, 12: 173–8.

    Article  CAS  PubMed  Google Scholar 

  15. Glascock MJ, Carty SE. Multiple endocrine neoplasia type 1: fresh perspective on clinical features and penetrance. Surg Oncol 2002, 11: 143–50.

    Article  PubMed  Google Scholar 

  16. Ferolla P, Falchetti A, Filosso P, et al. Thymic neuroendocrine carcinoma (carcinoid) in multiple endocrine neoplasia type 1 syndrome: the Italian series. J Clin Endocrinol Metab 2005, 90: 2603–8.

    Article  CAS  PubMed  Google Scholar 

  17. Trump D, Farren B, Wooding C, et al. Clinical studies of multiple endocrine neoplasia type I. Q J Med 1996, 89: 653–69.

    Article  CAS  Google Scholar 

  18. Gibril F, Venzon DJ, Ojeaburu JV. Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab 2001, 86: 5282–93.

    Article  CAS  PubMed  Google Scholar 

  19. Skogseid B, Laesson C, Lindgren PG, et al. Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type-1. J Clin Endocrinol Metab 1992, 75: 76–81.

    CAS  PubMed  Google Scholar 

  20. Langer P, Cupisti K, Bartsch DK, et al. Adrenal involvement in multiple endocrine neoplasia type 1. World J Surg 2002, 26: 891–6.

    Article  PubMed  Google Scholar 

  21. Barzon L, Pasquali C, Grigoletto C, Pedrazzoli S, Boscaro M, Fallo F. Multiple endocrine neoplasia type 1 and adrenal lesions. J Urol 2001, 166: 24–7.

    Article  CAS  PubMed  Google Scholar 

  22. Burgess JR, Shepherd JJ, Parameswaran V, et al. Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN1): clinical, biochemical and radiological features of pituitary disease in a large MEN1 kindred. J Clin Endocrinol Metab 1996, 81: 2642–6.

    CAS  PubMed  Google Scholar 

  23. Kaltsas GA, Bessere M, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004, 25: 458–511.

    Article  CAS  PubMed  Google Scholar 

  24. Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991, 12: 450–82.

    Article  CAS  PubMed  Google Scholar 

  25. Kwekkeboom DJ, Krenning EP. Somatostatin receptors imaging. In: Lamberts SWJ, Dogliotti L eds. The expanding role of octreotide I: advances in oncology. Bristol: BioScientifica Ltd. 2002, 17–30.

    Google Scholar 

  26. Beckers A, Betea D, ValdesSocin H, Stevenaert A. The treatment of sporadic versus MEN-I related pituitary adenomas. J Intern Med 2003, 253: 599–605.

    Article  CAS  PubMed  Google Scholar 

  27. Verges B, Boureille F, Goudet P, et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multi-center study. J Clin Endocrinol Metab 2002, 87: 457–65.

    Article  CAS  PubMed  Google Scholar 

  28. Shi W, Buchanan KD, Johnston CF, et al. The octreoscan suppression test and [111 In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment. Clin Endocrinol (Oxf) 1998, 48: 303–9.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to L. Tauchmanová MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nuzzo, V., Tauchmanová, L., Falchetti, A. et al. MEN1 family with a novel frameshift mutation. J Endocrinol Invest 29, 450–456 (2006). https://doi.org/10.1007/BF03344129

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03344129

Key-words

Navigation